TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04669626

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Use of Ocetnilin
Description: Visits to the outpatient wound-care centre as directed by a physician. Wound care performed by the respective study nurse according to the study-protocol. Each dressing change will be the same and will be as follows:~* Removal of old dressing~* Applying a soaked gaze with Octenilin® on the wound (5 minutes)~* Mechanical debridement if necessary~* Wound cleansing with Octenilin®~* Application of new dressing (according to the wound healing phases, medical prescription)

Intervention type: OTHER
Group type: OTHER
Intervention: Use of NaCl 0.9%
Description: Visits to the outpatient wound-care centre as directed by a physician. Wound care performed by the respective study nurse according to the study-protocol. Each dressing change will be the same and will be as follows:~* Removal of old dressing~* Applying a soaked gaze with NaCl 0.9% solution on the wound (5 minutes)~* Mechanical debridement if necessary~* Wound cleansing with NaCl 0.9% solution~* Application of new dressing (according to the wound healing phases, medical prescription)
Study: NCT04230135

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hap-pas-Hapi
Description: Hap-pas-Hapi is a Smartphone-based intervention for the treatment of psychological distress. It includes five sessions and uses a narrative approach. Behavioural activation is the main active therapeutic agent in the intervention, along with stress management, positive self-talk, mood tracking, social support, and relapse prevention.
Study: NCT01069822

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6765
Description: IV solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: midazolam

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: midazolam
Study: NCT01227733

Intervention type: OTHER
Intervention: Breast Tumor Blocks
Study: NCT04347707

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BRIDGE Therapy Program
Description: The BRIDGE Therapy Program is a novel structured form of therapy that incorporates key parenting concepts and related Dialectical Behavior Therapy (DBT) modules. The primary aim of the program is to promote self-regulation in the mother-child dyads. The program involves 20, once per week, scheduled group therapy sessions that last for 2 hours. There are two components of the program, the first is the DBT section, which will follow the DBT Skills Training Manual 2nd Edition and will target maternal mental health symptomology. The second section is the parent skill training materials, which have been designed to correspond to the 4 core DBT modules (Mindfulness, Emotion Regulation, Distress Tolerance, and Interpersonal Effectiveness) and to promote self-regulatory skill development and a positive parent-child relationship.
Study: NCT04230135

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hap-pas-Hapi
Description: Hap-pas-Hapi is a Smartphone-based intervention for the treatment of psychological distress. It includes five sessions and uses a narrative approach. Behavioural activation is the main active therapeutic agent in the intervention, along with stress management, positive self-talk, mood tracking, social support, and relapse prevention.
Study: NCT00929396

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 50 microg. antigen + adjuvant (500 nmol KLK + 20 nmol ODN1a)
Description: o,5 mL suspension for injection x 2 with 2 months interval

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 50 microg. antigen + adjuvant (500 nmol KLK + 20 nmol ODN1a)
Description: o,5 mL suspension for injection x 2 with 2 months interval
Study: NCT03975478

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Gastric bypass
Description: The GB technique consists of a 150-cm antecolic Roux limb with a 25-mm circular pouch-jejunostomy and exclusion of 50 cm of the proximal jejunum.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sleeve gastrectomy
Description: The SG technique consists of a longitudinal resection of the stomach from the angle of His to approximately 5 cm proximal to the pylorus, using a 35 French bougie inserted along the lesser curvature.
Study: NCT00479687

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SUPARTZ®
Description: Three Supartz injections over 2 weeks into the glenohumeral joint space.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Phosphate Buffered Saline
Description: Three phosphate buffered saline injections over 2 weeks into the glenohumeral joint space.
Study: NCT02841514

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Y10 Tooth Whitening system including the Y10 toothpaste and the Y10 device

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: OTC toothpaste and an unoperated Y10 device
Study: NCT02064413

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ESS310 (BAY1454032)
Study: NCT03980691

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Chidamide with CAR-T or TCR-T cell therapy
Description: HIV-1 specific therapy
Study: NCT01757249

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combined Oral Contraceptive Pill (Microgynon 30)
Description: Pre-IVF treatment for 8 weeks
Study: NCT01282619

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Huperzine A
Description: Sustained-Release Tablet, 400µg once a day, 24 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: huperzine A
Description: Tablet, 200µg twice a day, 24 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo orally twice a day
Study: NCT00498771

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Aquatic Exercise arm
Description: Participants will attend 12 classes of aquatic exercise program (2-3 classes/weekly). Each one hour class is held in warm water pool which is 89 degrees and 3.5'-4'deep.Classes include low impact, dynamic movements for warm up, stretching and breathing exercises, upper and lower body resistance training, and cool down activities. Participants will be evaluated for Circumference \& volumetric measurement of the affected limb, BMI, weight and height at the baseline, at 3rd week and at 6th week. Participant will complete a quality of life survey (QOL)at baseline, 6 week, 6 and 12 month.
Study: NCT04161703

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: focused ultrasound, diet and exercise
Description: Focused Ultra Sound using a device of Mabel6 DUO Ultra Cavitation Technology produced by DAEYANG MEDICAL CO., KOREA applied on the abdominal region which extending bilaterally from the line extending from mid-axilla to iliac crest, and above from center of diaphragm to the line extending between two iliac crests below.~an aerobic exercise 3 to5 times/week for 12 weeks in the form of walking on treadmill for 30 minutes with moderate intensity a weight maintenance diet, which ranged from 1700 kcal to 2200 kcal/day, which was calculated in an individual basis for each subject according to his BMR, throughout the study period (12 weeks) to ensure that the reduction in the circumference was due to the treatment intervention rather than due to their weight reduction

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: diet and exercise
Description: weight maintenance diet, which ranged from 1700 kcal to 2200 kcal/day, which was calculated in an individual basis for each subject according to his BMR, throughout the study period (12 weeks) to ensure that the reduction in the circumference was due to the treatment intervention rather than due to their weight reduction. All subjects in both groups (A \& B) followed an aerobic exercise 3 to5 times/week for 12 weeks in the form of walking on treadmill for 30 minutes with moderate intensity (moderate intensity = 12-14 according to Borg Scale). The beginning period will be 15 mints and increased gradually until reaching 30 mints per time.
Study: NCT04415671

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AD-214
Description: AD-214 is a recombinant Fc-fusion protein that selectively binds to CXCR4 to antagonise the SDF-1/CXCR4 axis.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AD-214
Description: AD-214 is a recombinant Fc-fusion protein that selectively binds to CXCR4 to antagonise the SDF-1/CXCR4 axis.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT02120183

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psycho-educational support group therapy
Description: Weekly sessions lasting 60 minutes. Topics addressed each week:~Week 1: Coping with the diagnosis of loved one and dealing with uncertainty~Week 2: Caring for the carer 1: Feeding your body (self-care, stress management, mindfulness concepts)~Week 3: Caring for the carer 2: Feeding your mind (challenging negative thinking habits)~Week 4: The emotions of caregiving (handling emotional reactivity)
Study: NCT00122980

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Red Cell Transfusions
Description: Red Blood Cell Transfusions

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Iron Chelation
Description: Iron Chelation Therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxyurea
Description: Hydroxyurea

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Phlebotomy
Description: Phlebotomy
Study: NCT01437904

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Outpatient Recovery
Description: Patients go home following Percutaneous nephrolithotomy

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: In hospital recovery
Description: Patients are hospitalized following Percutaneous nephrolithotomy
Study: NCT01257061

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Group 1
Description: Clemastine fumarate 1,0 mg/g + dexamethasone 0,5/g applied 2 times / day at lesion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Group 2
Description: Dexchlorpheniramine maleate 10 mg/g applied 2 times / day at lesion
Study: NCT03360318

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: elbow cast
Description: elbow cast

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Removable elbow brace
Description: Removable elbow brace
Study: NCT02082119

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated IMRT
Description: Hypofractionated IMRT
Study: NCT02228837

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pear

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04037696

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: General Health Promotion Approach
Description: The trained Research assistants will ask the subjects about the priority of engaging in any desirable health-related lifestyle practice as identified in the completed baseline questionnaires and to state a targeted goal that they perceive as the easiest to achieve. Each subject will then receive an individual face-to-face brief MI (about 5 mins) with generic health advice on selected health-related lifestyle practice. They will then be informed to receive an individual brief MI intervention to assist behavioural changes or achieve goals as desired or chosen by them via WeChat or WhatsApp in smart phones throughout the study period.~The RA will then deliver brief MI to each subject individually via WeChat or WhatsApp in smart phones throughout the study period.~Readiness of quitting smoking will be assessed at 3-month follow-up. Upon request by subjects, we shall provide them with more comprehensive information on quitting.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Control
Description: The subjects will be given general brief advice and a self-help smoking cessation booklet with Hotline (Tel.: 1833183). However, subjects in the control group will not receive brief MI and follow-up booster intervention.
Study: NCT00771108

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise
Description: For 16 weeks subjects will exercise from 30-60 minutes five times a week.
Study: NCT00935922

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Flaxseed
Description: Flaxseed omega-3 fatty acids and lignans
Study: NCT00522431

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone
Description: 2% gel
Study: NCT03791788

Intervention type: DIAGNOSTIC_TEST
Intervention: QFR assessment
Description: QFR measurement in order to evaluate functional significance of epicardial stenosis and to compare the response of QFR for worsening stenosis severity, FFR value as reference standard
Study: NCT03924609

Intervention type: DIAGNOSTIC_TEST
Intervention: Intensive screening / routine screening
Description: Recommendation and results of bone imaging such as bone scan or PET/CT, or bone CT /MR are collected.
Study: NCT00390546

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol
Study: NCT00631371

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab 10 mg/kg intravenous (IV) q8wks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temsirolimus
Description: Temsirolimus 25 mg IV weekly

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: Bevacizumab 10 mg/kg intravenous (IV) q8wks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Interferon-Alfa 9MU
Description: Interferon-Alfa 9MU SC TIW
Study: NCT03673007

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gift card to be used for contraceptives that is valued at 50% of cost of name-brand IUD (August 26, 2018-March 3, 2019)
Description: M-CARES will randomize allocation of vouchers (gift cards) for contraception valued up to 50% of inserting a name-brand IUD (e.g., Skyla, Paraguard, Mirena) for women with out of pocket costs at Planned Parenthood. This intervention occurred between August 18, 2018, and March 3, 2019.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gift card to be used for contraceptives that is valued at 100% of cost of name-brand IUD (March 4, 2019-March 31, 2023)
Description: M-CARES will randomize allocation of vouchers (gift cards) for contraception valued up to 100% of inserting a name-brand IUD (e.g., Skyla, Paraguard, Mirena) for women with out of pocket costs at Planned Parenthood. This intervention occurred after March 3, 2019.
Study: NCT00762892

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Raltegravir and truvada
Description: Raltegravir 400 mg po bid, truvada 1 tab q daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atazanavir, Norvir and Truvada
Description: Atazanavir 300 mg po q daily, Norvir 100 mg po q daily and Truvada 1 tablet po q daily
Study: NCT00916357

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Humalog

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Humalog
Study: NCT01803386

Intervention type: DEVICE
Intervention: EIM Measurements
Description: EIM measurements are taken by applying saline to the skin and placing a sensor on patients' muscles that will record electrical activity. Electrical current is generated by this machine, but patients will not be able to feel it. The electrical activity recorded is returned to the machine and analyzed by a computer.

Intervention type: DEVICE
Intervention: EIM Measurements
Description: EIM measurements are taken by applying saline to the skin and placing a sensor on patients' muscles that will record electrical activity. Electrical current is generated by this machine, but patients will not be able to feel it. The electrical activity recorded is returned to the machine and analyzed by a computer.
Study: NCT00916357

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Humalog

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Humalog

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Humalog

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Humalog

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Humulin-R

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Humulin-R

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Humulin-R

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Humulin-R

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Humulin-R

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Humulin-R

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant human hyaluronidase PH20 (rHuPH20)
Study: NCT00916357

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant human hyaluronidase PH20 (rHuPH20)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant human hyaluronidase PH20 (rHuPH20)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant human hyaluronidase PH20 (rHuPH20)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant human hyaluronidase PH20 (rHuPH20)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant human hyaluronidase PH20 (rHuPH20)
Study: NCT00935922

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Flaxseed
Description: Flaxseed omega-3 fatty acids and lignans
Study: NCT03768648

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical assessment
Description: EDSS (Kurtzke JF; 1983) and the modified MS functional composite (MSFC) score. MS history and MS treatment will be recorded

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ecological evaluation
Description: Virtual reality task : Urban DailyCog© and Actual reality

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ecological evaluation
Description: Virtual reality task : Urban DailyCog© and Actual reality

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Neuropsychological evaluation
Description: cognitive tests exploring information processing speed, attention/concentration, working and episodic memories and executive function

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuropsychological evaluation
Description: cognitive tests exploring information processing speed, attention/concentration, working and episodic memories and executive function
Study: NCT01570504

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ivermectin
Description: oral formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivermectin
Description: oral formulation
Study: NCT03630328

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cogni.Q
Description: AGN

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Cogni.Q
Description: AGN

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT00772954

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Vaccine diluent buffer
Description: 0.5 mL, Intramuscular at Day 0, Day 28 and Day 56, respectively.
Study: NCT03768648

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Psychological evaluation
Description: questionnaires for depression, anxiety and fatigue

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Psychological evaluation
Description: questionnaires for depression, anxiety and fatigue

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MRI Evaluation
Description: morphological MRI and resting state functional MRI (fMRI)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI Evaluation
Description: morphological MRI and resting state functional MRI (fMRI)
Study: NCT00772954

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Clostridium difficile toxoid vaccine (50 μg)
Description: 0.5 mL, Intramuscular at Day 0, Day 28 and Day 56, respectively.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Clostridium difficile toxoid vaccine (100 μg)
Description: 0.5 mL, Intramuscular on Day 0, Day 28 and Day 56, respectively.
Study: NCT04069897

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A
Description: Botulinum toxin 25 Allergan units in 0.5 ml Sodium Chloride (NaCl) 0.9 % Braun. Two injections, one in each side of the face, and targeting the sphenopalatine ganglion.
Study: NCT04584580

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: low-molecular-weight heparin
Description: low-molecular-weight heparin administered via subcutaneous injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: low-molecular-weight heparin
Description: low-molecular-weight heparin administered via subcutaneous injection
Study: NCT01773109

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etirinotecan pegol (NKTR-102)
Description: Eligible patients will receive etirinotecan pegol at a dose of 145 mg/m2 iv every 3 weeks. One cycle will be defined as 3 weeks. Treatment will be administered on an outpatient basis.
Study: NCT02706821

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Persimmon leaf extract
Description: Persimmon leaf extract (PLE), crossover design

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Persimmon leaf extract
Description: Persimmon leaf extract (PLE), crossover design

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo, crossover design

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo, crossover design
Study: NCT04069897

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 0.5 ml Sodium Chloride (NaCl) 0.9% Braun. Two injections, one in each side of the face, and targeting the sphenopalatine ganglion.
Study: NCT03489382

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Smartphone Assisted PST
Description: Emergency Departments randomized to the study intervention will receive:~1. Staff education incorporated into regular teaching rounds at least twice a year about the management of self-harm in the Emergency Department. This will include the dissemination of guidelines on how to ask questions about suicide, assessment of suicide risk, the creation of a management plan and how to refer patients to local mental health resources, including the study.~2. Written materials developed by service users for men who self-harm that outline local resources, distress centre helplines, and follow-up arrangements.~3. The option to refer men who self-harm to a service that will deliver smartphone-assisted PST specifically designed for men.
Study: NCT00665457

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Study: NCT00300196

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ancrod (Viprinex)
Description: 0.167 IU/kg/hr IV for 2-3 hours

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.6 mL/kg/hr
Study: NCT00665457

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: celecoxib